# Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease

> **NCT04691661** · PHASE2 · RECRUITING · sponsor: **Il-Yang Pharm. Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Radotinib HCl 50 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04691661
- **Lead sponsor:** Il-Yang Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-09
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04691661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04691661, "Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04691661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*